pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,499
stories
Aug 11, 26
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
Aug 11, 26
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
Aug 11, 26
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
stat
Aug 11, 26
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
Aug 10, 26
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
Aug 10, 26
STAT+: FDA panel to weigh Grail’s Galleri test
stat
Aug 10, 26
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
Aug 10, 26
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
Aug 10, 26
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
Aug 10, 26
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
Aug 10, 26
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
Aug 10, 26
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
stat
Aug 10, 26
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
fiercebiotech
Aug 10, 26
BioNTech vets get $25M seed funding for virtual cancer surveillance startup
endpoints
Aug 10, 26
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
Aug 10, 26
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
Aug 10, 26
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
stat
Aug 10, 26
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
Aug 10, 26
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
Aug 10, 26
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
biospace
Aug 10, 26
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
Aug 10, 26
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
Aug 7, 26
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
endpoints
Aug 7, 26
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
Aug 7, 26
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 7, 26
Is the biotech capital of the world moving?
stat
Aug 7, 26
A third clinic settles with DOJ over trans care
stat
Aug 7, 26
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
Aug 7, 26
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
fiercebiotech
← prev
page 24 of 50
next →
